Happy New Year and welcome back to the first Weekender of 2015! It’s jam-packed with excellent stories from a number of BioNJ Members and BioNJ.
By now we hope you’ve seen some of the exciting news about what’s going to take place at The Gateway Gala.
The meeting will start out on a strong note on Feb. 5 at the Hilton East Brunswick as we celebrate, with the assistance of
Lt. Governor Kim Guadagno, the innovation taking place in New Jersey at our research-based life science companies. And BioNJ’s Founding Chairman Dr. Abraham Abuchowski will be honored with the Dr. Sol J. Barer Award for Vison, Innovation and Leadership.
You can learn more in The Gateway Gala section of this week’s newsletter. And please stay tuned, because there is more exciting news coming.
The fast pace of the industry kept up during the holidays and into the New Year.
Soligenix was granted “fast-track” approval for SGX301, which is a first-line treatment of Cutaneous T-Cell Lymphoma while three BioNJ Members: Cornerstone Pharmaceuticals, Ipsen Biopharmaceuticals and Matinas BioPharma Holdings are making advancements in cancer and cholesterol therapies.
Advaxis was busy throughout the New Year, reporting that in collaboration with the GOG Foundation, they will collaborate on a global Phase III clinical trial of ADXS-HPV in cervical cancer. Advaxis also submitted an Investigational New Drug application to the FDA to conduct the first-in-human study of ADXS-HER2 (ADXS31-164) for the treatment of HER2 expressing solid tumors.
Hackensack University Medical Center was named the top New Jersey hospital for the third straight year in the U.S. News rankings, with 11 of its clinical specialties ranking with the top 50 hospitals nationwide.
With all the good news, this edition of The Weekender is one you won’t want to miss! May all the good news warm your heart during these cold winter days.
Click here to read this week’s Weekender.